

Decision number: CCH-D-2114292050-60-01/F

Helsinki, 27 February 2015

DECISION ON A COMPLIANCE CHECK OF A REGISTRATION PURSUANT TO ARTICLE 41(3) OF REGULATION (EC) NO 1907/2006**For Reaction products of propane-1,2-diol, propoxylated by amination of the terminal hydroxyl groups, EC No 618-561-0, registration number: [REDACTED]****Addressee: [REDACTED]**

The European Chemicals Agency (ECHA) has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Regulation).

I. Procedure

Pursuant to Article 41(1) of the REACH Regulation ECHA has performed a compliance check of the registration for Reaction products of propane-1,2-diol, propoxylated by amination of the terminal hydroxyl groups, EC No 618-561-0, submitted by [REDACTED] (Registrant). The scope of this compliance check is limited to the standard information requirements of Annex IX, Section 8.7.2. and Annex X, 8.7.3. of the REACH Regulation. ECHA stresses that it has not checked the information provided by the Registrant (and other joint registrants) for compliance with requirements regarding the identification of the substance (Section 2 of Annex VI).

This decision is based on the registration as submitted with submission number [REDACTED], for the tonnage band of 1000 tonnes or more tonnes per year. This decision does not take into account any updates submitted after 24 July 2014, the date upon which ECHA notified its draft decision to the Competent Authorities of the Member States pursuant to Article 51(1) of the REACH Regulation.

This compliance check decision does not prevent ECHA from initiating further compliance checks on the present registration at a later stage.

The compliance check was initiated on 23 September 2013.

On 28 November 2013 ECHA sent the draft decision to the Registrant and invited him to provide comments within 30 days of the receipt of the draft decision.

On 13 January 2014 ECHA received comments from the Registrant.

The ECHA Secretariat considered the Registrant's comments. On basis of this information, Section II and the Statement of Reasons (Section III) were modified.

On 24 July 2014 ECHA notified the Competent Authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals for amendment of the draft decision within 30 days of the receipt of the notification.

Subsequently, proposals for amendment to the draft decision were submitted.

On 29 September 2014 ECHA notified the Registrant of the proposals for amendments to the draft decision and invited him pursuant to Article 51(5) of the REACH Regulation to provide comments on the proposals for amendment within 30 days of the receipt of the notification.

The ECHA Secretariat reviewed the proposals for amendment received and did not amend the draft decision.

The present decision relates solely to a compliance check for the information requirement of a pre-natal developmental toxicity study (Annex IX, Section 8.7.2.). The information requirement for the two-generation study (Annex X, Sections 8.7.3.) will be addressed in a separate decision although these endpoints were initially addressed together in the same draft decision.

On 8 September ECHA referred the draft decision to the Member State Committee.

By 29 September 2014, in accordance to Article 51(5), the Registrant provided comments on the proposals for amendment. In addition, the Registrant provided comments on the draft decision. The Member State Committee took the comments of the Registrant on the proposals for amendment into account.

A unanimous agreement of the Member State Committee on the draft decision was reached on 13 October 2014 in a written procedure launched on 2 October 2014.

II. Information required

Pursuant to Articles 41(1), 41(3), 10(a)(vii), 12(1)(e), 13 and Annex X, of the REACH Regulation the Registrant shall submit the following information using the indicated test method and the registered substance subject to the present decision:

- Pre-natal developmental toxicity study in rats or rabbits, oral route (Annex IX, 8.7.2.; test method: EU B.31/OECD 414).

Pursuant to Article 41(4) of the REACH Regulation the Registrant shall submit the information in the form of an updated IUCLID dossier to ECHA by **7 March 2016**.

Notes for consideration by the Registrant:

In light of the comments made by the Registrant, ECHA points out that the Registrant may adapt the testing requested above according to the specific rules outlined in Annexes IX to X and/or according to the general rules contained in Annex XI of the REACH Regulation. In order to ensure compliance with the respective information requirement, any such adaptation will need to have a sound scientific justification, referring to and conforming with the appropriate rules in the respective Annex, and an adequate and reliable documentation.

Failure to comply with the request(s) in this decision, or to fulfil otherwise the information requirement(s) with a valid and documented adaptation, will result in a notification to the Authorities of the Member States for enforcement.

III. Statement of reasons

Pursuant to Article 41(3) of the REACH Regulation, ECHA may require the Registrant to submit any information needed to bring the registration into compliance with the relevant information requirements.

1. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.)

A "pre-natal developmental toxicity study" for a first species is a standard information requirement as laid down in Annex IX, Section 8.7.2. of the REACH Regulation. Adequate information on this endpoint needs to be present in the technical dossier for the registered substance to meet this information requirement.

In the technical dossier the Registrant provided information with which he sought to fulfil this standard information requirement. The provided information stems from a Reproductive/Developmental Toxicity Screening (OECD 421) study conducted on the registered substance. However, this study does not provide the information required by Annex IX, Section 8.7.2., e.g. because it does not cover key parameters of a pre-natal developmental toxicity study, such as examinations of foetuses for skeletal and visceral alterations.

The Registrant has proposed to adapt the information requirement of a prenatal developmental toxicity. The Registrant refers to corrosivity of the registered substance. ECHA recognises that according to introductory paragraph 4 of Annex IX of the REACH Regulation "in vivo testing with corrosive substances at concentration/dose levels causing corrosivity shall be avoided". ECHA would like to point out that according to the text of the relevant provision quoted above, non-corrosive concentration(s) can be tested. Introductory paragraph 4 is not a legal basis for adapting standard information requirements.

The Registrant is advised to examine how the concentration of the test substance can be adjusted to avoid corrosion allowing at the same time detection of potential systemic toxicity effects of the substance. The general principle of adjusting the concentration of the test substance to avoid corrosion and irritation is set out in the relevant test guidelines.

Therefore, the adaptation of the information requirement suggested by the Registrant cannot be accepted.

As explained above, the information available on this endpoint for the registered substance in the technical dossier does not meet the information requirement. Consequently there is an information gap and it is necessary to provide information for this endpoint.

In his comments submitted pursuant to Article 50(1) of the REACH Regulation, the Registrant agreed that, in the studies provided so far, the key parameters of the pre-natal developmental study are missing. Hence, the Registrant agrees to perform a pre-natal developmental toxicity study, as required.

According to the test method EU B.31/OECD 414, the rat is the preferred rodent species, the rabbit the preferred non-rodent species and the test substance is usually administered orally. ECHA considers these default parameters appropriate and testing should be performed by the oral route with the rat or the rabbit as a first species to be used. ECHA notes that in his comments the Registrant indicated his intention to test the rabbit as first species.

Therefore, pursuant to Article 41(1) and 41(3) of the REACH Regulation, the Registrant is requested to submit information on Pre-natal developmental toxicity on rats or rabbits (test method EU B.31/OECD 414) on the registered substance.

Notes for consideration by the Registrant:

In addition, a pre-natal developmental toxicity study on a second species is part of the standard information requirements as laid down in Annex X, Section 8.7.2. for substances registered for 1000 tonnes or more per year (see sentence 2 of introductory paragraph 2 of Annex X).

The Registrant should firstly take into account the outcome of the pre-natal developmental toxicity on a first species and all other relevant available data to determine if the conditions are met for adaptations according to Annex X, 8.7. column 2, or according to Annex XI; for example if the substance meets the criteria for classification as toxic for reproduction Category 1B: May damage the unborn child (H360D), and the available data are adequate to support a robust risk assessment, or alternatively, if weight of evidence assessment of all relevant available data provides scientific justification that the study in a second species is not needed. If the Registrant considers that testing is necessary to fulfill this information requirement, he should include in the update of his dossier a testing proposal for a pre-natal developmental toxicity study on a second species. If the Registrant comes to the conclusion that no study on a second species is required, he should update his technical dossier by clearly stating the reasons for adapting the standard information requirement of Annex X, 8.7.2.

Deadline for submitting the information

In the draft decision communicated to the Registrant the time indicated to provide the requested information was 30 months from the date of adoption of the decision. This period of time took into account the fact that the draft decision also included a request for a two-generation reproductive toxicity study (Annex X, 8.7.3.). As this endpoint is not addressed in the present decision, ECHA considers that a reasonable time period for providing the required information in the form of an updated IUCLID5 dossier is 12 months from the date of the adoption of the decision. The decision was therefore modified accordingly.

IV. Adequate identification of the composition of the tested material

ECHA stresses that the information submitted by the Registrant and by other joint registrants for identifying the substance has not been checked for compliance with the substance identity requirements set out in Section 2 of Annex VI of the REACH Regulation.

In relation to the information required by the present decision, the sample of substance used for the new studies must be suitable for use by all the joint registrants. Hence, the sample should have a composition that is within the specifications of the substance composition that are given by the joint registrants. It is the responsibility of all joint registrants who manufacture or import the same substance to agree on the appropriate composition of the test material and to document the necessary information on their substance composition.

In addition, it is important to ensure that the particular sample of substance tested in the new studies is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured by each registrant. If the registration of the substance by any registrant covers different grades, the sample used for the new studies must be suitable to assess these grades.

Finally there must be adequate information on substance identity for the sample tested and the grade(s) registered to enable the relevance of the studies to be assessed.

VI. Information on right to appeal

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such an appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on ECHA's internet page at http://echa.europa.eu/appeals/app_procedure_en.asp. The notice of appeal will be deemed to be filed only when the appeal fee has been paid.



Leena Ylä-Mononen
Director of Evaluation